Antagonists of protease activated receptor-1 (PAR1)
AssigneeIrm LLC
InventorsSteve B Cohen, Marc Nasoff
Life of this patent
Estimating the term…
Abstract
The present invention provides antibodies or antigen-binding molecules that specifically recognize and antagonize human PAR1 receptor. Also provided in the invention are polynucleotides and vectors that encode such molecules and host cells that harbor the polynucleotides or vectors.
Claims22
An antibody or antigen binding molecule that specifically binds to an epitope of human PAR1 which antibody or antigen binding molecule comprises heavy chain complementarity determining region (CDR) sequences CDR1, CDR2, and CDR3 of SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23, respectively;
- and light chain CDR sequences CDR1, CDR2, and CDR3 of SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively, and wherein the antibody or antigen binding molecule is a PAR1 antagonist.
An antibody or antigen binding molecule that specifically binds to an epitope of human PAR1, which antibody or antigen binding molecule comprises a heavy chain complementarity determining region (CDR) sequences CDR1, CDR2, and CDR3 of SEQ ID NO:27, SEQ ID NO:28 and SEQ ID NO:29, respectively;
- and light chain CDR sequences CDR1, CDR2, and CDR3 of SEQ ID NO:30, SEQ ID NO:31, and SEQ ID NO:32, respectively, and wherein the antibody or antigen binding molecule is a PAR1 antagonist.
A pharmaceutical composition comprising an antibody or antigen binding molecule that specifically binds to an epitope of human PAR1, wherein the antibody or antigen binding molecule comprises heavy chain CDR1, CDR2, and CDR3 sequences, SEQ ID NO:21, SEQ ID NO:22 and SEQ ID NO:23, respectively;
- and light chain CDR1, CDR2, and CDR3 sequences, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively, and wherein the antibody or antigen binding molecule is a PAR1 antagonist.
A pharmaceutical composition comprising an antibody or antigen binding molecule that specifically binds to an epitope of human PAR1, wherein the antibody or antigen binding molecule comprises heavy chain CDR1, CDR2, and CDR3 sequences, SEQ ID NO:27, SEQ ID NO:28 and SEQ ID NO:29, respectively;
- and light chain CDR1, CDR2, and CDR3 sequences, SEQ ID NO:30, SEQ ID NO:31, and SEQ ID NO:32, respectively, and wherein the antibody or antigen binding molecule is a PAR1 antagonist.
Dependencies are inferred from the claim text.